Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDuke University
About this trial
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Eligibility criteria
Qualifiers
Age ≥ 18 years of age
Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
Patient must sign study-specific informed consent
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
5Duke Cancer Institute Cary27518, CaryNorth Carolina, United States
Duke University Medical Center27710, DurhamNorth Carolina, United States
Durham Veterans Administration Health Care System (DVAHCS)27705, DurhamNorth Carolina, United States
Duke Raleigh Hospital27609, RaleighNorth Carolina, United States
Sponsors and collaborators
Duke University
Lead sponsor
Source ClinicalTrials.gov